Publications by authors named "B G Dharmanand"
Background: The ACR in 2021 and the EULAR in 2022 published recommendations for management of ANCA-associated vasculitis. Given the differences in the demographic, clinical profiles, and the socio-economic realities between various countries, there is a need for development of guidelines for the management of AAV for less economically developed regions of the world.
Methods: These guidelines were made following the GRADE methodology.
Background: We conducted this study to identify the influence of prolonged use of hydroxychloroquine (HCQ), glucocorticoids and other immunosuppressants (IS) on occurrence and outcome of COVID-19 in patients with autoimmune rheumatic diseases (AIRDs).
Methods: This was a prospective, multicenter, non-interventional longitudinal study across 15 specialist rheumatology centers. Consecutive AIRD patients on treatment with immunosuppressants were recruited and followed up longitudinally to assess parameters contributing to development of COVID-19 and its outcome.
Article Synopsis
- Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children, with anterior uveitis being a frequent related condition, although there is limited research on posterior segment issues.
- A case report details a 19-year-old Indian female with JIA who experienced worsening of her previously controlled anterior uveitis and new retinal inflammation after receiving anti-SARS-CoV-2 vaccinations.
- The incident highlights the importance of recognizing potential flare-ups in autoimmune conditions following vaccination, emphasizing the role of timely immunosuppressive treatments in managing these complications.
We report a case of exacerbation of posterior scleritis and orbital pseudotumor in a patient with granulomatosis polyangiitis, with initial rituximab infusion. Modifications in rituximab protocols including reduction in maintenance dose for subsequent infusions with increase in premedication dose of intravenous methyl prednisolone may be useful to prevent periinfusional flares. In this case report, we highlight a rare occurrence and modification in rituximab protocol to prevent post-infusional flare of inflammation.
View Article and Find Full Text PDF